6CM
CLYM

683 Capital Management’s Climb Bio CLYM Stock Holding History

683 Capital Management’s Portfolio CLYM Stock Details CLYM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-90,000
Closed -$617K – 252
2026
Q1 		$617K Sell
90,000
-111,652
-55% -$644K 0.03% 169
2025
Q4 		$807K Buy
+201,652
New +$484K 0.04% 159

Other funds holding CLYM

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

683 Capital Management's CLYM Position: Q2 2026 in Review

683 Capital Management sold out of Climb Bio (CLYM) in Q2 2026, closing a stake of 90,000 shares — an estimated $617K sold.

683 Capital Management first reported a position in CLYM in Q4 2025 and held it in 2 quarters. The position peaked at $807K in Q4 2025. 108 funds tracked by Wall St. Rank hold CLYM as of Q2 2026.

  • 683 Capital Management reported no remaining Climb Bio position as of Q2 2026 after selling out during the quarter.
  • 683 Capital Management sold 90,000 Climb Bio shares in Q2 2026, an estimated $617K.
  • 683 Capital Management first reported a position in Climb Bio in Q4 2025 and held it in 2 quarters.
  • 683 Capital Management's Climb Bio position peaked at $807K in Q4 2025.
  • 108 funds tracked by Wall St. Rank held Climb Bio as of Q2 2026.

Based on 683 Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.